



February 4, 2013

ImmunoCellular Therapeutics to Present at BIO CEO & Investor Conference on February 11th

LOS ANGELES--(BUSINESS WIRE)-- ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") (NYSE MKT: IMUC) today announced that Andrew Gengos, Chief Executive Officer of ImmunoCellular, will present a corporate overview and business update at the 15th Annual BIO CEO & Investor Conference on Monday, February 11, 2013 at 10:00 am ET at the Waldorf Astoria Hotel in New York City.

To access the live audio webcast of the BIO CEO presentation, please log on through a link located in the Investor Relations section of ImmunoCellular's website at www.imuc.com, under the Investors, Webcasts and Presentations tab. A replay of the webcasts will be available one hour after the conclusion of the live event.

In addition, John S. Yu, M.D., ImmunoCellular Founder, Chairman and Chief Scientific Officer, will present a talk titled "Active Immunotherapy for Cancer Stem Cells" at the 20th International Molecular Medicine Tri-Conference, at 11 am PT on Tuesday, February 12, in San Francisco.

About ImmunoCellular Therapeutics, Ltd.

ImmunoCellular Therapeutics, Ltd. is a Los Angeles-based clinical-stage company that is developing immune-based therapies for the treatment of brain and other cancers. ImmunoCellular is conducting a Phase II trial of its lead product candidate, ICT-107, a dendritic cell-based vaccine targeting multiple tumor-associated antigens for glioblastoma. ImmunoCellular's pipeline also includes ICT-121, a dendritic cell vaccine targeting CD133, and ICT-140, a dendritic cell vaccine targeting ovarian cancer antigens and cancer stem cells. To learn more about ImmunoCellular, please visit www.imuc.com.

For ImmunoCellular Therapeutics, Ltd.
Jane Green.
Investor Relations
415.348.0010
jane@jmgcomm.com

Source: ImmunoCellular Therapeutics, Ltd.

News Provided by Acquire Media